Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
X-ray repair cross-complementing protein 6 (XRCC6), also known as Ku70, is a critical component of the non-homologous end joining (NHEJ) pathway for DNA double-strand break repair. It forms a heterodimer with Ku80 (XRCC5), binding to DNA ends with high affinity and shielding them from nucleolytic degradation, while recruiting additional repair factors including DNA-dependent protein kinase catalytic subunit (DNA-PKcs), XRCC4, and Ligase IV[1][3][4][6]. Ku70 is also essential for V(D)J recombination in lymphocyte development, telomere maintenance, and modulation of apoptosis via interaction with proteins such as Bax and p53. Beyond nuclear functions, Ku70 acts as a cytosolic DNA sensor, activating innate immune responses, and serves as a cell-surface receptor in bacterial internalization. Mutation or altered expression of XRCC6 is implicated in cancer, neurodegeneration, and immune disorders. As a therapeutic target, its primary relevance is for modulating DNA repair in cancer therapy and as a marker for disease susceptibility and treatment response[3][5].
Inhibition of non-homologous end joining by targeting components of DNA-PK (including Ku70/Ku80/DNA-PKcs complex) reduces DNA repair capacity and sensitizes cells to DNA damage Ku70 may be targeted to sensitize tumor cells to radiation or DNA-damaging agents Modulation of immune sensing pathways (cytosolic DNA sensing via Ku70)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on X-ray repair cross-complementing protein 6 (XRCC6).